MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, is pleased to announce that it has completed the delivery of its largest order of ArtemiC to US distribution and marketing partner, AMC Holdings Inc. (AMC).
Delivery to AMC Holdings
As announced in MGC Pharma’s market release titled “Operations Update” on 20 October 2022, AMC Holdings, amended the terms of its US$1,000,000 order of ArtemiC Rescue, with the product to be delivered in a single shipment, and to be ready for immediate supply in the US owing to increasing demand.
Delivery of this large consignment of ArtemiC has now been completed, marking the first substantial commercial delivery of the product under the AMC US supply and distribution agreement to date.
Brent W. Yessin of AMC commented, “AMC are excited to bring the first commercial order of ArtemiC into the US.
“It will be available both on-line and through independent pharmacies. Since the pandemic, the federal government has stopped paying for many treatments the cost burden has shifted to the individual states and consumers.
“With this change in policy AMC are pleased to be in a position offer the market a natural, plant based and clinically tested treatment option.”